Zai Lab of Shanghai announced China 's NMPA approved the use of Zejula® (niraparib), a PARP inhibitor, as a first-line maintenance treatment for ovarian cancer. In December 2019, Zejula was approved for use in second or third-line maintenance therapy in China . Zai recently started a China bridging trial for the drug as a late-line treatment for ovarian cancer. In 2016, Zai acquired Greater China rights to the drug from Tesoro Pharma, now a part of GSK. More details.... Stock Symbol: (NSDQ: ZLAB) Share this with colleagues: // //